The U.S. Food and Drug Administration (FDA) has approved Ubrelvy (ubrogepant) tablets for immediate treatment of migraine with or without aura in adults. Ubrelvy is not indicated for the preventive treatment of migraine. It is the first drug in the class of oral calcitonin gene-related peptide receptor antagonists approved for the acute treatment of migraine.… Continue reading New Migraine Treatment Approved for Adults